Travere Therapeutics. has been granted a patent for a method of PEGylating a mutated human truncated cystathionine ß-synthase protein (htCBS C15S). The method involves using NHS ester PEG molecules and in-process monitoring to enhance PEGylation, demonstrating efficacy in treating homocystinuria. GlobalData’s report on Travere Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Travere Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Travere Therapeutics's grant share as of June 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Pegylation method for mutated human cystathionine ß-synthase protein
The granted patent US12042529B2 outlines a method for PEGylating a specific human truncated cystathionine ß-synthase (CBS) protein, identified as htCBS C15S, which contains a mutation where cysteine at position 15 is replaced by serine. The method involves conjugating htCBS C15S with a variety of NHS ester PEG molecules in solution, utilizing a molar excess of these molecules that can be up to 20-fold. The PEG molecules can vary in size, specifically being 5 kDa, 10 kDa, or 20 kDa. The process includes a comparative analysis using non-reduced capillary electrophoresis (NR-CE) to assess the retention time of the PEGylated batch against a standard sample that has been confirmed to have acceptable PEGylation, defined as having at least five PEGylated sites. If the batch's retention time is less than that of the standard, additional NHS ester PEG molecules are added to enhance the PEGylation.
The claims further specify variations in the molar excess of NHS ester PEG molecules, allowing for amounts less than 20-fold, 10-fold, 5-fold, or even 2-fold. Additionally, the claims detail that the plurality of NHS ester PEG molecules can consist solely of one specific size, such as 5 kDa, 10 kDa, or 20 kDa, with a stipulation that each molecule is less than about 20 kDa. This method aims to optimize the PEGylation process for htCBS C15S, potentially improving its therapeutic applications by enhancing its stability and solubility.
To know more about GlobalData’s detailed insights on Travere Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
